{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Will be defined as the proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) in the evaluable population.","groups":[{"description":"Patients receive sintilimab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.\n\nSintilimab: Given IV","id":"OG000","title":"Treatment (Sintilimab)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"2 participants not evaluable at 12 weeks (passed away)","reportingStatus":"POSTED","timeFrame":"At 12 weeks","title":"Best Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}